"During the first half of FY24, the pipeline for new installed...

"During the first half of FY24, the pipeline for new installed base and upgrades continued to grow
however timeframes to conclude sales increased resulting in lower capital sales than expected. In
particular, this saw the Company experience softer than anticipated upgrade sales with customers
extending the use of their existing trophon equipment, delaying the trophon2 upgrade capital
purchase. Based on the Company’s current sales pipeline and the opportunities for ongoing pipeline
growth in both new installed base and upgrades, the Company is expecting both capital unit and
revenue growth in H2 over H1 and is currently undertaking a detailed review of the full year outlook.
Further, we are also reviewing a number of additional customer offerings to support our customers
to upgrade capital units earlier without impacting the longer term value of a Trophon unit."

I am disappointed with this report. It is a hospital based budgetary quandary. But as far as T2 is concerned it should not matter all that much. T2 price does not break the bank.
I remain convinced that the move to total NAN directed sales is the right move and it was in the pipeline for 5 yrs under the direction of Mr Sargant a former GE executive.
The Feb 26 HF will be all about CORIS and its FDA approval and commrcialisation